Proxima's mission is to unlock a new chapter in medicine by making protein interactions programmable.
The company has developed an integrated discovery platform built on three complementary, phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. These technologies are powered by generative AI and advanced data generation to accelerate drug discovery.
Proxima collaborates with industry leaders and has secured significant funding, including an $80 million seed round backed by DCVC and Nvidia, to advance AI-driven therapeutics. The company focuses on programmable protein interactions, enabling a new generation of precision medicines.
